- Total Voting Rights
- Notice of Results
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- Total Voting Rights and Block Listing Return
- Signing of Strategic Platform License
- MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- Exercise of options and PDMR dealing
- Grant of Options, RSUs and PSUs and PDMR Dealing
- Filing of form 10-K for FY ended December 31, 2023
- Reports Q4 & FY 2023 Financial Results
More ▼
Key statistics
On Thursday, MaxCyte Inc (MXCT:NSQ) closed at 3.83, 56.33% above the 52 week low of 2.45 set on Oct 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.80 |
---|---|
High | 3.85 |
Low | 3.62 |
Bid | 3.68 |
Offer | 4.08 |
Previous close | 3.78 |
Average volume | 502.81k |
---|---|
Shares outstanding | 104.40m |
Free float | 97.75m |
P/E (TTM) | -- |
Market cap | 394.62m USD |
EPS (TTM) | -0.3675 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼